Literature DB >> 34607004

Functions of the (pro)renin receptor (Atp6ap2) at molecular and system levels: pathological implications in hypertension, renal and brain development, inflammation, and fibrosis.

Nadin Hoffmann1, Jörg Peters2.   

Abstract

The (pro)renin receptor [(P)RR, Atp6ap2] was initially discovered as a membrane-bound binding partner of prorenin and renin. A soluble (P)RR has additional paracrine effects and is involved in metabolic syndrome and kidney damage. Meanwhile it is clear that most of the effects of the (P)RR are independent of prorenin. In the kidney, (P)RR plays an important role in renal dysfunction by activating proinflammatory and profibrotic molecules. In the brain, (P)RR is expressed in cardiovascular regulatory nuclei and is linked to hypertension. (P)RR is known to be an essential component of the v-ATPase as a key accessory protein and plays an important role in kidney, brain and heart via regulating the pH of the extracellular space and intracellular compartments. V-ATPase and (P)RR together act on WNT and mTOR signalling pathways, which are responsible for cellular homeostasis and autophagy. (P)RR through its role in v-ATPase assembly and function is also important for fast recycling endocytosis by megalin. In the kidney, megalin together with v-ATPase and (P)RR is crucial for endocytic uptake of components of the RAS and their intracellular processing. In the brain, (P)RR, v-ATPases and megalin are important regulators both during development and in the adult. All three proteins are associated with diseases such as XLMR, XMRE, X-linked parkinsonism and epilepsy, cognitive disorders with Parkinsonism, spasticity, intellectual disability, and Alzheimer's Disease which are characterized by impaired neuronal function and/or neuronal loss. The present review focusses on the relevant effects of Atp6ap2 without assigning them necessarily to the RAS. Mechanistically, many effects can be well explained by the role of Atp6ap2 for v-ATPase assembly and function. Furthermore, application of a soluble (P)RR analogue as new therapeutic option is discussed.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  (Pro)renin receptor; Autophagy; Endocytosis; Hypertension; Inflammation; Kidney and brain; Megalin; Renin-angiotensin-system; v-ATPase

Mesh:

Substances:

Year:  2021        PMID: 34607004     DOI: 10.1016/j.phrs.2021.105922

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  4 in total

Review 1.  Unraveling the Differentially Articulated Axes of the Century-Old Renin-Angiotensin-Aldosterone System: Potential Therapeutic Implications.

Authors:  Pitchai Balakumar; Shaminder Handa; Ali Alqahtani; Taha Alqahtani; Noohu Abdulla Khan; R Sulochana LakshmiRaj; A Thangathirupathi; Karupiah Sundram; Vinayak Shenoy
Journal:  Cardiovasc Toxicol       Date:  2022-02-10       Impact factor: 3.231

2.  Blood Pressure Elevation of Tubular Specific (P)RR Transgenic Mice and Lethal Tubular Degeneration due to Possible Intracellular Interactions between (P)RR and Alternative Renin Products.

Authors:  Sae Saigo; Tabito Kino; Kotaro Uchida; Takuya Sugawara; Lin Chen; Michiko Sugiyama; Kengo Azushima; Hiromichi Wakui; Kouichi Tamura; Tomoaki Ishigami
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

3.  Positive Association Between Plasma Aldosterone Concentration and White Matter Lesions in Patients With Hypertension.

Authors:  Yujuan Yuan; Nanfang Li; Yan Liu; Qing Zhu; Mulalibieke Heizhati; Weiwei Zhang; Xiaoguang Yao; Deilian Zhang; Qin Luo; Menghui Wang; Guijuan Chang; Mei Cao; Keming Zhou; Lei Wang; Junli Hu; Nuerguli Maimaiti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

4.  The Nephrotoxin Puromycin Aminonucleoside Induces Injury in Kidney Organoids Differentiated from Induced Pluripotent Stem Cells.

Authors:  Lisa Nguyen; Wasco Wruck; Lars Erichsen; Nina Graffmann; James Adjaye
Journal:  Cells       Date:  2022-02-11       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.